Lurie, G;
Wilkens, LR;
Thompson, PJ;
Shvetsov, YB;
Matsuno, RK;
Carney, ME;
Palmieri, RT;
... Ovarian Canc Assoc Consortium; + view all
(2011)
Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium.
PLOS ONE
, 6
(6)
, Article e20703. 10.1371/journal.pone.0020703.
![[thumbnail of 1311499.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1311499.pdf Download (288kB) |
Abstract
The association of ovarian carcinoma risk with the polymorphism rs1271572 in the estrogen receptor beta (ESR2) gene was examined in 4946 women with primary invasive ovarian carcinoma and 6582 controls in a pooled analysis of ten case-control studies within the Ovarian Cancer Association Consortium (OCAC). All participants were non-Hispanic white women. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression adjusted for site and age. Women with the TT genotype were at increased risk of ovarian carcinoma compared to carriers of the G allele (OR = 1.10; 95%; CI: 1.01-1.21; p = 0.04); the OR was 1.09 (CI: 0.99-1.20; p = 0.07) after excluding data from the center (Hawaii) that nominated this SNP for OCAC genotyping A stronger association of rs1271572 TT versus GT/GG with risk was observed among women aged <= 50 years versus older women (OR = 1.35; CI: 1.12-1.62; p = 0.002; p for interaction = 0.02) that remained statistically significant after excluding Hawaii data (OR = 1.34; CI: 1.11-1.61; p = 0.009). No heterogeneity of the association was observed by study, menopausal status, gravidity, parity, use of contraceptive or menopausal hormones, tumor histological type, or stage at diagnosis. This pooled analysis suggests that rs1271572 might influence the risk of ovarian cancer, in particular among younger women.
| Type: | Article |
|---|---|
| Title: | Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0020703 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pone.0020703 |
| Language: | English |
| Additional information: | © 2011 Lurie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The Ovarian Cancer Association Consortium: a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith. HAW: the U.S. National Institutes of Health (R01 CA58598, N01-CN-55424, N01-PC-67001); USC: Public Health Service grants CA14089, CA17054, CA61132, CA63464, N01-PC-67010 and R03-CA113148, and California Department of Health Services sub-contract 050-E8709; UKO: Cancer Research UK, the Eve Appeal, the OAK Foundation and the Department of Health's NIHR Biomedical Research Centre funding scheme; STA: the U.S. National Institutes of Health/National Cancer Institute: U01CA71966, R01CA16056, U01CA69417, and K07CA143047; SEA: Cancer Research United Kingdom; POL: Intramural Funds from the U.S. National Cancer Institute, National Institutes of Health, Division of Cancer Epidemiology and Genetics (POL) National Cancer Institute R01-CA-76016 (NCO); NCO: the National Cancer Institute R01-CA-76016; MAL: Mermaid 1, the Danish Cancer Society and the National Cancer Institute R01-CA-61107; The Australian Ovarian Cancer Study and Australian Cancer Study: US Army Medical Research and Material Command (DAMD17-01-1-0729), Cancer Council Victoria, Cancer Council Queensland, Cancer Council New South Wales, Cancer Council South Australia, Cancer Council Tasmania and Cancer Foundation of Western Australia, USC: the California Cancer Research Program grants 00-01389V-20170 and 2110200, U.S. Public Health Service grants CA14089, CA17054, CA61132, CA63464, N01-PC-67010 and R03-CA113148, and California Department of Health Services sub-contract 050-E8709 the National Health and Medical Research Council of Australia (199600 and 400281). PMW and GCT are funded by fellowships from the National Health and Medical Research Council of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Keywords: | MESSENGER-RNA EXPRESSION, ER-BETA, GENETIC POLYMORPHISMS, DOWN-REGULATION, CARCINOGENESIS, SUSCEPTIBILITY, BREAST, CELLS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1311499 |
Archive Staff Only
 |
View Item |
